Why is Balaji Amines on a nosedive

Balaji Amines , a prominent aliphatic amines manufacturer in India, has had its share of ups and downs. Over the last 10 years, it has delivered an impressive annual return of 52.5 per cent (as of September 27, 2023). However, recent setbacks have taken a toll on its stock price, which plummeted by 32 per cent over the past year. Let's delve into the issues plaguing Balaji Amines.

Resignations rattle investors

The company's Board witnessed a significant shake-up in Q1 FY24. In May 2023, five independent Directors - Naveena Thammishetty Chandra, Kashinath Revappa Dhole, Satyanarayana Murthy Chavali, Amarender Reddy Minupuri, and Vimala Behram Madon - tendered their resignations.

Initially attributed to "personal reasons," this mass exodus sent shockwaves through the market, causing a 15 per cent drop in share price. Subsequently, the company clarified that these resignations were prompted by SEBI's regulations, which impose a 10-year term limit for independent directors.

IPO plans abandoned, results delayed

Balaji Amines had been gearing up for an IPO of its subsidiary, Balaji Speciality Chemicals. They submitted the draft prospectus to SEBI in August 2022 and secured approval. However, the IPO faced constant delays and was ultimately withdrawn on September 8, 2023.

Further compounding the woes, the company postponed the release of its quarterly results. Citing management's involvement in the subsidiary's IPO, the Q1 FY24 results were only disclosed on August 31, 2023, nearly two months after the quarter ended. These delays, coupled with the board changes, led to the company losing the market's favour.

Performance lags behind peers

Balaji Amines has been grappling with declining sales, both year-on-year and sequentially, over the past five quarters. Q1 FY24 was no exception, with revenue and net profit plummeting by 31 per cent and 54 per cent, respectively. While management attributed this downturn to rising raw material prices, rising competition from Chinese imports, and sluggish demand from the pharmaceutical segment, it's worth noting that a smaller peer, Alkyl Amines, experienced a less severe decline.

Furthermore, FY23 witnessed a concerning 38 per cent spike in Balaji Amines' inventory days, resulting in a two-decade high in its cash conversion cycle. This aligns with a worrying trend that has persisted in recent years.

The road ahead

Despite these challenges, the management remains optimistic, claiming that chemical prices have hit rock bottom, and planned capital expenditures offer hope for a turnaround. However, the cash conversion cycle and underperformance compared to peers raise valid concerns. Additionally, while the company cited SEBI regulations as the reason for director resignations, investors are advised to monitor the situation closely.

In conclusion, Balaji Amines, once a standout performer, is now grappling with a series of issues that have eroded its stock price and investor confidence. The path ahead remains uncertain, with recovery hinging on a combination of macro factors and management actions.

Also read: Raymond's remarkable renaissance